2006
DOI: 10.1590/s0021-75572006000400002
|View full text |Cite
|
Sign up to set email alerts
|

Calendário vacinal na infância e adolescência: avaliando diferentes propostas

Abstract: Objectives: To present the criteria used to define a vaccination schedule for childhood and adolescence, comparing the recommendations of national and international excellence institutions.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
2
0
7

Year Published

2010
2010
2020
2020

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(11 citation statements)
references
References 6 publications
0
2
0
7
Order By: Relevance
“…School non-enrollment was assessed from 4 and 6 years of age. Vaccination coverage was explored in children 24 months and older because most of the childhood vaccinations recommended by the Brazilian Ministry of Health are administered before the age of 15 months 25 . Vaccination coverage for a vaccine-preventable illness (VPI) was considered complete if the recommended number of doses was administered before 24 months -adequate timing of the doses was disregarded.…”
Section: Discussionmentioning
confidence: 99%
“…School non-enrollment was assessed from 4 and 6 years of age. Vaccination coverage was explored in children 24 months and older because most of the childhood vaccinations recommended by the Brazilian Ministry of Health are administered before the age of 15 months 25 . Vaccination coverage for a vaccine-preventable illness (VPI) was considered complete if the recommended number of doses was administered before 24 months -adequate timing of the doses was disregarded.…”
Section: Discussionmentioning
confidence: 99%
“…Estimase que o potencial de proteção para a doença pneumocócica invasiva causada pelos sorotipos constantes na vacina PCV7 seja de 70% e que apresente imunidade de grupo 7,8 . A partir de 2008, 24 países incorporaram a vacina na rotina de imunização, principalmente na América do Norte e na Europa Ocidental 9,10 . Em 2009 e 2010, a pneumocócica 13-valente (PCV13) foi licenciada no Chile, na Europa e nos Estados Unidos para uso em crianças com idades entre seis semanas e 71 meses, em substituição à PCV7 11,12,13 .…”
Section: Introductionunclassified
“…Several publications discuss indications of special immunobiologicals or describe the care to specific groups in the CRIE 3 , 5 , 6 , 21 , 24 , 26 , but we did not find studies that evaluate the implementation of CRIE in national perspective.…”
Section: Introductionmentioning
confidence: 74%